TMTPOST — Chinese digital healthcare and medical technology company DXY (Dingxiangyuan) has officially launched preparations for a Hong Kong initial public offering (IPO), with plans to submit its prospectus to the Hong Kong Stock Exchange (HKEX) as early as 2025. Founded in July 2000, DXY has grown into one of China’s largest digital health platforms, serving both the general public and medical professionals. The platform boasts over 9 million registered professional users, accounting for roughly 80% of the country’s healthcare personnel, including 4.05 million licensed physicians — representing 92% of China’s total. For general consumers, DXY offers a broad range of health services, including health education content, online consultations, and a health product e-commerce platform. The company has developed multiple sub-brands, such as Dingxiang Doctor, Dingxiang Mom, and Dingxiang Home, to serve diverse health and lifestyle needs. On the professional side, DXY focuses on supporting physicians’ career development, providing tools for academic exchange, continuing education, drug guidance, and professional growth. Its suite of products includes popular offerings like the Medication Assistant, DXY Insight, DXY Talent, and DXY Open Courses, widely used across China’s medical community. DXY has attracted significant investor attention over the years. In December 2020, the company raised $500 million in a major financing round, fueling its expansion in both consumer health services and professional medical tools. The upcoming Hong Kong IPO represents a key step in DXY’s strategy to further scale its digital health ecosystem, strengthen its market position, and broaden its access to capital for continued growth in China and potentially overseas markets.